

AUA2021 May Kick-off Weekend
 Trimodality Therapy for Management of Muscle Invasive Bladder Cancer
 May 22, 2021

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Faculty Disclosures:

<u>Name</u>	<u>Company</u>	<u>Role</u>	<u>Financial</u>
Adam Feldman, MD	Olympus America, Inc	Consultant or Advisor	Yes
	Janssen Pharmaceuticals	Meeting Participant or Lecturer	Yes
	Vessi Medical	Consultant or Advisor	Yes
Richard Lee, MD	Janssen LLC	Scientific Study or Trial	Yes
Jason Efstathiou, MD	Uptodate	Health Publishing	Yes
	BlueEarth Diagnostics	Consultant or Advisor	Yes
	Boston Scientific	Consultant or Advisor	Yes
	AstraZeneca Pharmaceuticals	Consultant or Advisor	Yes
	Merck	Consultant or Advisor	Yes
	Myovant Sciences	Consultant or Advisor	Yes
	Progenics	Consultant or Advisor	Yes